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Genome-wide transcriptomic effects of phytoestrogens in breast
cancer cells
Abstract
The nutritional intake of phytoestrogens seems to reduce the risk of breast cancer or other neoplastic
diseases. However, these epidemiologic findings are controversial because low phytoestrogen doses,
achievable through soy-rich diets, stimulate the proliferation of estrogen-sensitive tumor cells. The
question of whether such phytochemicals prevent cancer, or pose additional health hazards, led us to
monitorglobal gene expression changes induced by phytoestrogens (daidzein, coumestrol, enterolactone,
resveratrol) or a typical soy product (soymilk), from which the phytochemicals were extracted by
reverse/normal phase chromatography. In each case, phytoestrogens were used to treat human cells
representing a common model system for mammary tumorigenesis. Analysis of messenger RNA on
highdensity microarrays revealed that soy phytoestrogens induce a genomic fingerprint that is
indistinguishable from the transcriptional effects of the physiologic hormone 17β-estradiol. Highly
congruent responses were also observed by comparing the physiologic estradiol with phytoestrogen
standards. More diverging transcriptional profiles were generated when an inducible promoter was used
to reconstitute the expression of estrogen receptor β. We conclude that phytoestrogens mitigate
estrogenic signaling in the presence of both estrogen receptor subtypes but, in late-stage cancer cells
lacking estrogen receptor β, these phytochemicals may contribute to a tumor-promoting transcriptional
signature.
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1.  Summary 
 
The nutritional intake of phytoestrogens seems to reduce the risk of breast cancer 
or other neoplastic diseases. However, these epidemiologic findings are 
controversial because low phytoestrogen doses, achievable by soy-rich diets, 
stimulate the proliferation of estrogen-sensitive tumor cells. The question of 
whether such phytochemicals prevent cancer, or pose additional health hazards, led 
us to monitor global gene expression changes induced by phytoestrogens 
(daidzein, coumestrol, enterolactone, resveratrol) or a typical soy product 
(soymilk), from which the phytochemicals were extracted by reverse/normal phase 
chromatography. In each case, phytoestrogens were used to treat human cells 
representing a common model system for mammary tumorigenesis. Analysis of 
messenger RNA on high-density microarrays revealed that soy phytoestrogens 
induce a genomic fingerprint that is indistinguishable from the transcriptional 
effects of the hormone 17β-estradiol. Highly congruent responses were also 
observed by comparing the physiologic estradiol with phytoestrogen standards. 
More diverging transcriptional profiles were generated when an inducible 
promoter was used to reconstitute the expression of estrogen receptor β. We 
conclude that phytoestrogens mitigate estrogenic signaling in the presence of both 
estrogen receptor subtypes but, in late-stage cancer cells lacking estrogen receptor 
β, these phytochemicals may contribute to a tumor-promoting transcriptional 
signature. 
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2.  Introduction 
 
2.1 Estrogen receptors 
 
2.1.1 Structure  
 
There are two principal intracellular receptors that mediate the biological effects of 
estrogens: estrogen receptor α (ERα) and estrogen receptor β (ERβ). ERs belong 
to the steroid nuclear receptor superfamily, one of the largest protein families with 
more than 70 currently recognised members (Mangelsdorf et al., 1995). Nuclear 
receptors are ligand-activated transcription factors that regulate the expression of 
target genes involved in metabolism, cell proliferation, differentiation, growth, 
reproduction and development (Mangelsdorf et al., 1995; Enmark & Gustafsson, 
1999; Penot et al., 2005; Moutsatsou, 2007). 
ERα and ERβ are both composed of five independent but interacting functional 
domains (Fig. 1): the N-terminal domain (A/B), the DNA-binding domain (C), the 
hinge region (D), the ligand-binding domain (E) and the C-terminal domain (F). 
 
 
 
 
 
Figure 1: Schematic representation of human estrogen receptors 
 
 
The N-terminal domains exhibit strong distinctions between ERα and ERβ (they 
share less than 20% amino acid identity) and contain the ligand-independent 
transcription activation function (AF-1), which is responsible for recruiting 
transcriptional co-activator proteins and exerts promoter- and cell specific activity. 
The ER subtypes α and β differ in the activity of AF-1: ERαAF-1 is very active in 
the stimulation of target gene expression from a variety of estrogen responsive 
reporter constructs, whereas the activity of ERβAF-1, under the same conditions, is 
generally reduced (Webb et al., 1999; Kuiper et al., 1996; Nilsson, 2001; Howell 
A, 2006). 
In contrast, the DBD (DNA-binding domain) is a highly conserved structure where 
ERα and ERβ share a high degree of sequence identity (Matthews, 2003). The 
DBD consists of two zinc fingers that participate in receptor dimerisation (by 
 3 
forming hydrogen and ionic bonds with the zinc fingers of another ER) and 
mediate the binding to specific DNA sequences, termed HRE (hormone-responsive 
elements, i. e. ERE, for estrogen-responsive elements), within the promoter region 
of target genes.  
ERα and ERβ share 56% sequence identity (Koehler et al., 2005) in the ligand-
binding domain (LBD), which lies in the C-terminal half of the receptor protein 
and includes the ligand-dependent AF-2 (activation function 2). AF-2 performs a 
direct ligand interaction and mediates receptor dimerisation, nuclear translocation 
and the recruitment of co-activator proteins (Muelller et al., 2004; Barkhem et al., 
2002) leading to transactivation of target genes (Jacobs, 2002; Nilsson, 2001). The 
highest performance, i. e. full transcriptional activity, of the ligand-bound ER is 
achieved when AF-1 and AF-2 cooperate in a synergistic manner (Wärnmark & 
Gustaffson, 2003). Crystallographic studies with ERα and ERβ revealed that the 
AF-2 interaction surface is altered in its conformation by the binding of specific 
ligands. Also, different ligands induce different receptor conformations that allow 
discrimination between ER agonists and antagonists. Only the agonistic interaction 
leads to the recruitment of co-activators (Nilsson, 2001).  
The ligand specificity of ERs is determined by the surface chemistry of the binding 
cavity: amino acid residues lining the binding site interact with functional groups 
of the ligand molecule. Although ERα and ERβ vary to a great extend in the LBD, 
the amino acids of the binding cavity are much more highly conserved (Ekena et 
al., 1998; Koehler et al., 2005). Furthermore, the three-dimensional structures of 
the two ER subtypes are very similar despite the fact that the overall ligand-
binding cavity of ERβ is about 20% smaller than that of ERα. These subtle 
differences are thought to be responsible for the selective affinity and 
pharmacologic activity of distinct ligands. 
Between the DBD and LBD lies the flexible hinge region of the ER which plays a 
role in the sterical orientation of the nuclear receptor. It appears to be important for 
the nuclear translocation and has been reported to contain a nuclear localization 
signal (Picard et al.,1990). The C-terminal F-domain of the receptor protein 
displays less than 20% amino acid identity between the two ER subtypes and the 
functions of this domain remain undefined. Koide et al. (2007) postulate that the F-
domain of ERα modulates the response to ligands by regulating the interaction 
with transcriptional co-activators.  
Full-length ERα consists of 595 amino acids, whereas full-length ERβ contains 
only 530 amino acids (Penot et al., 2005). For both receptor subtypes, however, 
different isoforms that vary in their molecular activity and biological function 
(Omoto et al., 2003) have been reported. Some of these isoforms have extended 
amino-termini, others have truncations and/or insertions at the carboxy-terminus 
and in the LBD region (Leygue et al., 1996; Ogawa et al., 1998; Moore et al., 
1998; Nilsson et al., 2001; Tong et al., 2002; Matthews & Gustafsson, 2003). 
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2.1.2 Mechanism of action 
 
In the absence of ligands, the inactive ERs are sequestered in a multiprotein 
complex containing various molecular chaperones, including heat shock proteins 
(Pratt, 1997), in the nuclear compartment. The interaction with ligands induces the 
removal of chaperones (Hall, 2001; McDonnel, 2002), thus inducing 
conformational changes of the ER proteins that lead to dimerisation (either 
forming homo- or heterodimers, ERα-ERα, ERβ-ERβ or ERβ-ERα). These active 
ER dimers bind to estrogen-responsive elements (ERE) on the DNA and allow the 
recruitment of co-regulatory proteins and other transcription factors to induce or 
repress the transcription of genes (Pace et al., 1997; Matthews & Gustafsson, 
2003; Koehler et al., 2005; Suzuki et al., 2007). Each ERE acts as a cis-acting 
enhancer or transcriptional repressor located within the regulatory region of target 
genes (Hall, 2002, Jacobs, 2002; Nilsson, 2001). Binding of an agonist triggers 
AF-2 activity, leading to the recruitment of co-activators, whereas binding of an 
antagonist does not (Nilsson et al., 2001; Matthews & Gustafsson, 2003). 
There are also hints for signalling pathways that deviate from this classical model 
(see Figure 2). In fact, about one third of the genes known to be regulated by ERs 
in human cells do not contain ERE sequences, indicating additional mechanisms of 
gene regulation (Björnström & Sjöberg, 2005). One non-classical mode of action 
by which ERs can exert their influence on gene transcription is a process referred 
to as transcription factor cross talk/ERE-independent genomic actions. Following 
this model, ERs interact in the presence of E2 with general transcripton factors 
such as AP-1 (activating protein 1) or Sp-1 (stimulating protein 1), thus forming 
multiprotein complexes that also regulate transcription of genes that do not contain 
EREs in their promoter region (Salvatori et al., 2003). For example co-factors that 
function as bridging elements between ERα and AP-1 response elements 
(Barkhem et al., 2002) can trigger or enhance transcription of genes that do not 
have an ERE. AP-1 transcription factors are considered immediate early-response 
genes involved in a wide range of regulatory processes linked to cellular 
proliferation and differentiation. AP-1 is the gene product of the Jun and Fos 
oncogenes and is composed of either homo- or heterodimers of the Jun and Fos 
family members. Examples of factors induced by Era/AP-1 cross-talks include 
IGF-I, collagenase and cyclin D1. Conversely, the choline acetyltransferase gene is 
repressed by the ER/AP-1 complex. The interaction of ERs with Sp-1 results in the 
induction of LDL-R (low-density lipoprotein receptor), c-fos and cyclin D1 
(Nilsson, 2001; Barkhem et al., 2002; Björnström & Sjöberg, 2005).  
There is also a ligand-independent action of ERs, which is modulated by cell cycle 
regulators, extracellular signals (cytokines, neurotransmitters, peptide growth 
factors) and protein kinases, resulting in phosphorylation of ERs in the absence of 
estradiol (Nilsson et al., 2001; Hall et al., 2001; Björnström & Sjöberg, 2005; 
Buttet al., 2005).  
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Non-genomic actions are associated with a non-nuclear fraction of ERs, likely to 
be located in the cytosol or bound to the cell membrane, that mediates a rapid, 
transcription-independent response to estrogens leading to altered functions of 
cellular proteins. Non-genomic effects are for example observed in endothelial 
cells, where estradiol leads to the release of nitric oxide (NO), or in neurons, where 
estradiol induces neuroprotective effects via MAPK-activation (Moggs & 
Orphanides, 2001; Nilsson, 2001; Björnström & Sjöberg, 2005). 
 
 
 
 
Figure 2: 
Schematic illustration of different ER signalling mechanisms 
1. Classical mechanism of ER action: ligand-activated ERs bind directly to EREs 
in target gene promoters. 2. ERE-independent genomic actions: ER complexes are 
tethered through protein-protein interactions to a transcription factor complex 
(TF) that makes contacts with the target gene promoter. 3. Ligand-independent 
genomic actions: growth factors (GF) activate protein kinase cascades, leading to 
phosphorylation (P) and activation of nuclear ERs. 4. Non-genomic actions: 
Membrane-bound ERs activate protein-kinase cascades, leading to altered 
functions of proteins in the cytoplasm, e.g. activation of eNOS (endothelial nitric 
oxide synthase), or to regulation of gene expression through phosphorylation 
(adapted from Björnström & Sjöberg, 2005). 
 
 6 
2.1.3 Ligands 
 
Endogenous estrogens (primarily 17β-estradiol) are the natural and best fitting 
ligands of the ERs. Nevertheless, other similar molecules, like phytoestrogens, are 
potential ligands for the ERs as long as their structure resembles that of 17β-
estradiol (Nilsson et al., 2001). Common structural elements of the phytoestrogens 
and 17β-estradiol include a phenolic ring with a pair of hydroxyl groups, which are 
a precondition for binding to ERs. DES (diethylstilbestrol), which is lacking the 
steroid structure, is still able to bind to ERs in light of its two symmetric phenolic 
rings. DES (containing two phenolic rings) and resveratrol (containing one 
phenolic and one dihydroxylated phenolic ring) show high structural similarity, but 
differ significantly in their relative binding affinities for ERα and ERβ (Table 1). 
The binding affinity of a ligand to a certain receptor type is unable to predict 
whether the effect is agonistic or antagonistic (Bowers et al., 2000; Mueller et al., 
2004), i.e., to predict whether the ligand up- or down regulates the transcription of 
target genes. The effect exerted by a specific ligand can be assessed by comparing 
downstream transcriptional activities. Mueller et al. concluded that coumestrol, 
equol (a human metabolite of daidzein) and resveratrol are, like DES and 17β-
estradiol, full receptor agonists. Enterolactone, on the other hand, was classified as 
a partial agonist and partial antagonist because it reduces the transcriptional 
activity of DES bound to ERs. Similarly, resveratrol was identified as a mixed ER 
agonist/antagonist: at low doses (up to 10 µM) it increases the DES-induced ER 
activity but at high doses (100 µM) resveratrol inhibits the activity of ERs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Classification of dietary estrogens 
Isoflavones
eg
Genistein
Daidzein ( Equol)
Flavones
eg
Quercetin
Kaempferol, Hesperetin
Flavonoids
eg
Enterolactone
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eg
 Resveratrol
Stilbenoids
eg
   Coumestrol
Coumestans
Phytoestrogens Mycoestrogens Ovarian Steroids
Naturally Occuring
  Growth Promoters
 eg
Diethylstilbestrol
Xenoestrogens
eg
DDT, PCB
Synthetic Contaminants
Dietary Estrogens
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Phytoestrogens are polyphenolic non-steroidal plant compounds with estrogen-like 
biological activity, present in several edible plants. On the basis of their chemical 
structure, phytoestrogens may be divided into four subclasses: flavonoids (several 
subgroups: e.g. isoflavones, flavones), stilbenoids, coumestans, and lignans (Figure 
3). The major dietary sources of isoflavones (e.g. genistein, daidzein, 
formononetin, biochanin A) are soybeans, legumes in general, chickpeas and 
peanuts. Flavones (e.g. chrysin, apigenin, naringenin, quercetin) are more widely 
distributed in the plant kingdom and are present in citrus fruits, green tea, gingko, 
chocolate and wine. Coumestans (e.g. coumestrol, wedelolactone) are present for 
example in legumes, spinach, clover, brussel sprouts and also in alfalfa sprouts. 
Mammalian lignans (e.g. enterolactone and enterodiol) are not present in the 
human diets as such, but are ingested as precursors (plant lignans), which are 
converted to mammalian lignans by gut microflora. Plant lignans (e.g. pinoresinol, 
lariciresinol, secoisolariciresinol, matairesinol, sesamin) are present in fiber-rich 
foods such as flaxseed, sesame seed, pumpkin seed, broccoli and grain products. 
Stilbenoids, like resveratrol, can be found mainly in the skin of red grapes and 
unprocessed peanuts (Murkies, 1998, Nilsson et al., 2001; Moutsatsou, 2007). 
  
 
 
 ERα 
IC50 
 
RBA 
(ERα) 
 
ERβ 
IC50 
 
RBA 
(ERβ) 
 
DES 4.6 ± 1.0 nM  100 4.6 ± 1.5 nM 100 
E2 4.3 ± 1.1 nM 107 5.7 ± 0.7 nM 82 
Coumestrol 38 ± 15 nM 12 6.0 ± 3.6 nM 77 
Enterolactone 6.7 ± 4.3 µM 0.07 39 ± 22 µM 0.01 
Equol (Daidzein) 1.5 ± 0.5 µM 0.3 0.2 ± 0.01 µM 3 
Resveratrol 7.7 ± 2.3 µM 0.06 29 ± 20 µM 0.02 
 
 
Table 1: 
Relative binding affinities (RBA) of estradiol and phytoestrogens for human ERα 
and ERβ (Mueller et al., 2004) 
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17β-estradiol: 
 
 
 
 
 
 
 
 
DES:                  Resveratrol: 
 
 
 
 
 
 
 
    Enterolactone: 
 
 
 
 
 
 
 
 
                 Coumestrol: 
 
 
 
 
 
Daidzein: 
 
 
 
 
Figure 4: 
Chemical structure of the phytoestrogens coumestrol, daidzein, enterolactone, 
resveratrol, the endogenous hormone 17β-estradiol and DES 
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2.1.4 Distribution of the estrogen receptors 
 
An important aspect in understanding the estrogenic effects of phytoestrogens is 
the different tissue distribution and the level of expression of the two ERs. 
Although the ERs show high homology in their molecular structure, their tissue 
distribution is very variable (Kuiper et al., 1997; Gustafsson et al, 1999). While 
ERα is mainly expressed in the uterus, vagina, kidney and liver, ERβ is 
predominantly expressed in the cardiovascular system, urinary tract, lungs, thyroid, 
skin, gastro-intestinal tract and cartilage as well as bones. In humans, an almost 
concomitant expression of the two ERs can be found in the central nervous system, 
in the mammary tissue, ovaries and testes.  
For a better understanding of the multiple biological functions of the respective 
estrogen receptors, homozygous ERα, ERβ and ERαβ knockout (KO) mice have 
been generated using gene-targeting techniques (Krege et al., 1998, Couse & 
Korach, 1999; Enmark & Gustafsson, 1999; Walker & Korach, 2004). All three 
KO models were viable. The ERαKO, ERβKO and ERαβKO offspring develop in 
their genetically determined sexes with no morphological peculiarities in their 
reproductive tracts and organs, which is proving that the phenotypical sex does not 
depend on ER status. 
However effects resulting from the respective ER knockout(s) appear with onset of 
puberty. In ERαKO and ERαβKO, both sexes are infertile. The uteri of the 
ERαKO and ERαβKO are insensitive to estradiol and hypoplastic in all major 
uterine constituents (myometrium, endometrial stroma, epithelium), resulting in 
uterine weights that are approximately one half the expected size relative to the 
wild-type littermates (Walker & Korach, 2004). Their ovaries are anovulatory, 
secrete increased amounts of estradiol, testosterone and FSH (follicle-stimulating 
hormone) and develop hemorrhagic cysts due to chronic elevated LH (luteinizing 
hormone). This dysregulation of hormone homeostasis is due to the loss of ERα 
function in the hypothalamus, which leads to a failure of the negative feedback 
action of estradiol on the hypothalamic-pituitary axis (Couse et al., 2003; Walker 
& Korach, 2004). The testes of the male ERαKO and ERαβKO have normal 
morphology but after puberty they show progressively decreasing weight, the 
sperms have poor motility and the seminiferous tubules exhibit dilatation due to 
fluid retention.   
In the ERβKO mice, the females show reduced fertility that manifests itself in 
infrequent pregnancies and reduced litters. The males show normal morphology 
and fertility when compared to wild-type controls. In accordance with these 
findings, there are no obvious morphological phenotypes in ERβKO males and 
only slight alterations of the ovaries, resulting in a reduced ovulation rate, can be 
found in the female ERβKO mice. The uterus is of physiological structure and 
hormone responsiveness, and allows for normal pregnancies. The mammary gland 
does also exhibit normal structure and supports normal lactation (Krege et al., 
1998). In the double knockout mice (ERαβKO), the granulosa cells of some 
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follicles in the ovaries undergo differentiation into Sertoli-like cells and resemble 
the seminiferous tubules of the testis, suggesting the possibility of an adult sex 
reversal (Couse, 1999). The mammary glands of the ERαKO and ERαβKO mice 
are immature and remain rudimentary after puberty. As the elevated estrogen 
levels do not result in an increased progesterone receptor gene expression and the 
prolactine serum concentration remains very low compared to wild-type 
littermates, this effect is also attributable to disruption of the hypothalamic-
pituitary axis (Walker & Korach, 2004). The mating behaviour of male and female 
ERβKO mice is not altered when compared to wild-type controls. However, both 
sexes of the ERαKO and ERαβKO are disturbed in their mating behaviour (Couse 
et al., 2001). 
 
2.2 Phytoestrogens as endocrine disruptors 
 
Endocrine disruptors are exogenous chemicals that possess the ability to interfere 
with the endocrine system either by mimicking or antagonising the effects of 
endogenous hormones. Endocrine-disrupting chemicals are thought to cause a wide 
range of adverse health effects, including reproductive deficits, developmental 
disorders and cancer (Colborn et al., 1993; Cooper et al, 1997; McLachlan, 2001; 
Jobling, 2006; Caserta et al, 2007). The US Environmental Protection Agency 
defines an endocrine disruptor as an „exogenous agent that interferes with the 
synthesis, secretion, transport, binding, action or elimination of natural hormones 
in the body that are responsible for the maintainance of homeostasis, reproduction, 
development and/or behaviour“ (Jacobs, 2001). 
Endocrine disruptors comprise a variety of chemical classes including several 
pharmaceutical agents, synthetic hormones (DES), plant metabolites 
(phytoestrogens), fungal metabolites (mycoestrogens), pesticides, fungicides or 
herbicides and many industrial products and pollutants (Lathers, 2002). Endocrine-
disrupting chemicals are almost ubiquitously dispersed in the environment. Some 
of these compounds are highly persistent and have the potential for 
bioaccumulation and global distribution by long-distance transport. Other 
endocrine disruptors are rapidly degraded in the environment or by the organisms 
that incorporate them (Cooper, 1997; Safe, 2004; Jacobs, 2001; McLachlan, 2001; 
Campi, 2007). There is growing awareness for possible risks of such substances 
among consumers, authorities, environmental organisations and other stakeholders 
(Colborn et al., 1993; Cassidy, 2003). 
The present thesis is concerned with the effects of phytoestrogens in modulating 
the function of ERα and ERβ. Previous epidemiological studies have linked an 
increased risk of developing mammary or endometrial malignancies to prolonged 
estrogen exposure associated with early menarche, oral contraceptives, nulliparity, 
late first-time pregnancy, delayed menopause or an estrogen replacement therapy 
(McPherson et al., 2000; Clemons & Gross, 2001; Nelson et al., 2002; Parodi et 
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al., 2005). In contrast, the elevated dietary intake of soy isoflavones such as 
genistein and daidzein correlates with a lower incidence of breast and prostate 
cancer (Ingram et al., 1997; Murkies et al., 1998). In Asian countries, where soy 
provides a main food source, breast cancer incidence is two thirds lower compared 
to western countries. These epidemiologic findings led to the perception that 
phytoestrogen-rich foods and food supplements are generally healthy (Balk, 2002; 
Rice, 2006). Therefore, various soy products have become extremely popular, 
including soy oil, soy isoflavones as dietary supplements and as remedy for 
menopausal discomfort, soy flour, soy-based infant formula, tofu and soymilk. 
However, the true health effects of phytoestrogens from soy or other sources 
remain highly controversial. Some studies indicate that they exert beneficiary 
effects in preventing breast cancer, other reports suggest that the same compounds 
may be able to promote breast cancer or have other adverse effects on the 
endocrine system (Setchell et al., 1998; Glazier et al., 2001; Parodi et al., 2005; 
Patisaul, 2005; Ju, 2006; Moutsatsou, 2007; Wuttke et al., 2007; Sebastian et al., 
2007; Gallo et al., 2007; Duffy et al., 2007). 
In the normal resting mammary gland estrogen receptors are expressed in only a 
small proportion of epithelial cells that are largely non-dividing (Ali & Coombes, 
2002). In contrast, enhanced expression of ERs is a critical event in the 
pathogenesis of a majority (~ 70%) of breast cancers and, accordingly, the growth 
of malignant mammary tumours is estrogen-dependent in most cases (Hayashi et 
al., 1997; Gruvberger et al., 2001; Rice & Whitehead, 2006). Like other ER 
agonists, phytoestrogens stimulate the proliferation of estrogen-sensitive tumor 
cells in various experimental systems (Hsie et al., 1998; Allred et al., 2001) and 
this growth-promoting activity has raised concerns that soy products, or other 
dietary components containing similar phytochemicals, may represent an 
additional health hazard for vulnerable risk groups (Messina et al., 2006). More 
scepticism regarding the true benefits of phytoestrogens came from the observation 
that hyperplasia of the mammary epithelium is detectable in breast biopsies of pre- 
and postmenopausal women after a period of dietary soy supplementation (Petrakis 
et al., 1996; Hargreaves et al., 1999). Thus, establishing the consequences of soy 
intake in specific populations at high risk for breast cancer is an important public 
health issue (Messina et al., 2006). 
 
2.3  Aim of the study 
 
The aim of this study was to assess the ERα/ERβ mediated effects on gene 
regulation of some representative phytoestrogens (enterolactone, resveratrol, 
daidzein, coumestrol) both as single compounds and as complex dietary mixtures 
in vitro. To achieve comparability of the results, we also determined the effects of 
the endogenous hormone 17β-estradiol. Genome-wide transcriptional profiles have 
been determined in an estrogen-dependent human cell line (MCF7) that often 
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serves as a model system to study cellular processes related to cancer progression 
in the breast. The distinction between ERβ– and ERα–mediated effects was 
achieved with an ERβ-inducible T47D cell line. 
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3.  Materials 
 
3.1 Cell culture 
 
Cell culture media (DMEM, Ham’s F12, MEM) were obtained from Invitrogen, 
Grand Island, USA. FBS was purchased from HyClone Laboratories, USA; the 
xenoestrogen-free plastics were from Corning Inc., Grand Island, USA. 
 
PUCK’s EDTA  
0.40 g KCl  
8 g NaCl  
0.35 g NaHCO3  
1 g D-Glucose  
0.255 g 0.02 % EDTA  
ad 1000 ml aqua dest. 
Filtered through a 0.2 µm filter and stored at 4°C.  
 
3.2 Chemicals and equipment 
 
Chemicals: 
 
The antibiotics (gentamycin, tetracycline, streptomycin, penicillin) were from 
Invitrogen. Daidzein and resveratrol were purchased from Sigma-Aldrich, St 
Louis, USA; 17β-estradiol, coumestrol and enterolactone were purchased from 
Fluka (Buchs, Switzerland). 
 
 
Technical equipment for transcriptomics: 
 
Agilent 2100 Bioanalyzer: Agilent Technologies, Inc., Santa Clara, USA 
Hybridization Oven 640: Affymetrix®, P/N 8000139 (220V) 
Fluidics Station 400: Affymetrix®, P/N 00-0079 
GeneChip Scanner 3000: Affymetrix®, P/N 00-00212 
 
 
Reagents and solutions used for hybridization, washing and staining of the DNA 
microarrays: 
 
10 mg/mL goat IgG stock  
50 mg goat IgG are resuspended in 5 ml of 150 mM NaCl and stored at 4°C. 
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Wash buffer A (non-stringent wash buffer), 1000 ml: 
(6x SSPE, 0.01% Tween-20)  
300 ml of 20x SSPE  
1 ml of 10% Tween-20  
699 ml of water  
Filtered through a 0.2 µm filter  
 
Wash buffer B (stringent wash buffer), 1000 ml: 
(100 mM MES, 0.1 M NaCl, 0.01% Tween-20)  
83.3 ml of 12x MES stock buffer  
5.2 ml of 5 M NaCl  
1 ml of 10% Tween-20  
910.5 ml of water  
Filtered through a 0.2 µm filter, stored at 4°C and shielded from light  
 
2x Stain buffer, 250 mL: 
(100 mM MES, 1 M NaCl, 0.05% Tween-20)  
41.7 ml of 12x MES stock buffer  
92.5 ml of 5 M NaCl  
2.5 ml of 10% Tween-20  
113.3 ml of water  
 
12x MES stock buffer, 1000 ml, pH 6.5 – 6.7 
(1.22 M MES, 0.89 M NaCl)  
64.61 g of MES hydrate  
193.3 g of MES sodium salt  
800 ml of water  
The volume is adjusted to 1000 ml and the solution is filtered through a 0.2 µm 
filter. 
  
2x Hybridization buffer, 50 ml 
(Final concentration is 100 mM MES, 1 M NaCl, 20 mM EDTA, 0.01% Tween-
20)  
8.3 ml of 12x MES stock buffer  
17.7 ml of 5 M NaCl  
4 ml of 0.5 M EDTA  
0.1 ml of 10% Tween-20  
19.9 ml of water  
Stored at 4°C and  shielded from light 
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3.3 Kits 
 
The following kits were purchased from Affymetrix, Santa Clara, USA: 
- RNeasy Mini kit: QIAGEN®, P/N 79306 
- IVT Labeling kit 
- One-Cycle cDNA Synthesis kit 
 - Sample Cleanup Module 
 - Poly–A RNA Control kit 
 - Hybridization Control kit  
 - Hybridization, Wash and Stain kit 
 
 
3.4 Microarrays 
 
The Affymetrix HG-U133 Plus 2.0 microarrays allow for the analysis of the 
expression level of approximately 40’000 human transcripts. The oligonucleotide 
probes, 25 residues in length, are bound to a solid support. Eleven pairs of 
oligonucleotide probes are used to measure the level of transcription of each 
sequence. To detect background fluorescence resulting from unspecific 
hybridisation, a paired mismatch probe for every perfect match probe is included 
on the array. 
 
 
 
4.  Methods 
 
4.1 Cell culture 
 
The MCF7 cell line, subtype BUS, kindly provided by Dr. Anna Soto, Tufts 
University, Boston, USA, is derived from a human female breast adenocarcinoma. 
It is positive for the ERα and β, though ERα expression is highly predominant 
(Vladusic, 2000). It is an estrogen-dependent cell line with a doubling time of 
approximately 25 to 30 hours. Cell stocks were stored in liquid nitrogen.  
Prior to seeding, cells were thawed at 37 °C, transferred into sterile tubes (Falcon’s 
50 ml), diluted with warm complete DMEM (Dulbecco’s Modified Eagle’s 
Medium, containing 1000 mg/l glucose) and supplemented with 10% fetal bovine 
serum (FBS, Invitrogen), 0.1 U/ml penicillin and 0.1 mg/ml streptomycin). The 
cells were collected by centrifugation (5 minutes, 1000 rpm, 4 °C), resuspended in 
complete warm medium and transferred into 75 cm2 xenoestrogen-free cell culture 
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flasks (Corning Inc., Grand Island, USA). The cell culture was carried out at 37°C 
in saturated humid atmosphere under 5% CO2. The culture medium was changed 
every 12 – 20 hours. 
After the cells grew to 85 – 95% confluence (every second to third day), they were 
split at a ratio of 1:3. For subculturing, the cells were washed with prewarmed 
sterile PUCK’s EDTA, trypsinised (1:30 dilution with PUCK’s EDTA), collected 
in 10 ml complete medium and centrifuged for 5 minutes at 1’000 rpm. The 
supernatant was removed, the cell pellet was resuspended in warm complete 
medium and transferred to the cell culture flasks. 
Before each experiment, the cells were rinsed with 37°C warm PUCK’s EDTA and 
the complete DMEM medium was changed to phenol red-free assay medium 
supplemented with 5% charcoal/dextran-stripped FBS (DCC-FBS) containing the 
previously indicated antibiotics. The cells remained for 48 hours in this estrogen-
deprived milieu, with a medium change after 24 hours. Finally, test compounds 
were dissolved in dimethyl sulfoxide (DMSO) and added to the estrogen-free assay 
medium. The final DMSO concentration was adjusted to 0.1% (v/v). 
 
T47D-ERβ  cells were kindly provided by Dr. Jan-Åke Gustaffson, Karolinska 
Institute, Huddinge, Sweden. The T47D cell line is an epithelial, differentiated 
strain of the female ductal carcinoma cell line T47 and has a doubling time of 
approximately 32 hours. 
By withdrawal of tetracycline, this stably transfected cell line expresses the 
estrogen receptor β together with EGFP (enhanced green fluorescent protein). 
Thus, the expression of the ERβ can be monitored upon UV illumination without 
any substrates or cofactors (Ström et al., 2004). 
The cells are stored in liquid nitrogen and, prior to culture, they are thawed at 
37°C, sterile-transferred to a Falcon tube containing warm complete DMEM 
(DMEM/F12 supplemented with 5% FBS, sodium bicarbonate, the previously 
indicated antibiotics and 1 µg/ml tetracycline) and then centrifuged for 5 minutes 
at 1’000 rpm. The cell pellet is resuspended in 10 ml warm complete medium, 
transferred to a 75 cm2 culturing flask and put in the incubator at 37°C, saturated 
humidified air and 5% CO2. 
When cells have grown to subconfluence (80 – 95%), subculturing is carried out in 
a 1:3 ratio. First, the cells are washed with warm PUCK’s EDTA. Then cells are 
trypsinised with 2 ml 1:30 Trypsin/PUCK’s EDTA and the flask is gently slapped 
with the palm of the hand to detach all cells. The cells are then collected in 10 ml 
of complete medium in a 50 ml Falcon tube and spun down for 5 minutes at 1’000 
rpm. After removing the supernatant, the cell pellet is resuspended in 10 ml 
complete medium and the cells are split in a 1:3 ratio into 75 cm2 culturing flasks. 
Before conducting an experiment, the cells are starved in estrogen-free and phenol 
red-free assay medium for 48 hours. For the ERβ assay the subcultered cells were 
divided into two groups: one group nourished with estrogen-free assay medium 
supplemented with 1 µg/ml tetracycline; the other group, for induction of ERβ, 
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was grown in assay medium without tetracycline. 
 
T47D.Luc cells (BioDetection Systems, Amsterdam, NL) were maintained in a 1:1 
mixture of DMEM and Ham’s F12 medium supplemented with sodium 
bicarbonate, 1 mM L-glutamine and 7.5% FBS. Before performing the ER-
CALUX assay, T47D.Luc cells were seeded in 96 wells microtiter plates (Corning 
Inc, Garnd Island, USA) at a density of 5,000 cells per well in 100 µl phenol red-
free medium containing 5% DCC-FBS. The outlining rows were left blank in order 
to prevent desiccation of cells. 
After 48 hours in this estrogen-deprived milieu, with a medium renewal after 24 
hours, the indicated test compounds, dissolved in DMSO, were added. Blank and 
solvent controls and a standard 17β-estradiol dose response were included on each 
plate. After 24 hours exposure time, the assay medium was sucked off and the cells 
were lysed and assayed for luciferase activity on a Dynex microplate luminometer 
(Legler et al. 1999). 
 
 
4.2  Cytotoxicity assay: resazurin cell viability assay (AlamarBlue® assay) 
 
AlamarBlue (resazurin) is a safe (non-toxic, non-carcinogenic) aqueous dye to 
assess cell viability by monitoring the mitochondrial activity. Upon reduction by 
the mitochondrial coenzymes (FMNH2, FADH2, NADH, NADPH) the 
AlamarBlue® dye shows a change in colour and turns from blue (oxidised) into the 
red fluorescent resorufin derivative, thus indicating that the cells are vital. 
 
Resazurin       resorufin 
 
 
The intensity of this colour change is measured in a microplate photometer at 565 
nm for absorption and at wavelengths of 535 nm (excitation) and 595 nm 
(emission) for fluorescence. This assay was used to test the effect of the solvent 
DMSO as well as the cow- and soymilk extracts. Untreated cells served as negative 
control, cell-free wells served as blank controls. The assay was performed in 96-
well-plates (Corning Inc., Grand Island, USA) with each well containing 5’000 
cells and 100 µl of the specific assay medium. The outlining rows were left blank 
with complete growth medium. 
After 24 hours of exposure, the test was performed by adding the AlamarBlue dye, 
100 µl per well. The cells were further incubated (humidified air, 5% CO2, 37 °C) 
until photometric measurements were carried out. 
 
 
NADH/ H+ NAD+. H2O 
 18 
4.3 ER-CALUX Assay 
 
The ER-CALUX (chemical-activated luciferase gene expression) assay is a 
recombinant receptor reporter gene assay based on the induction of 
bioluminescence in the stably transfected cell line T47D.Luc (Legler et al., 1999). 
It is a very sensitive, highly responsive and fast screening method for the 
estrogenicity of chemical compounds (detection limit for 17β-estradiol: 0.5 pM). 
The stably transfected cells display a chromosomally integrated pEREtata-Luc 
construct containing three tandem repeats of the consensus ERE sequence (5’-
GGTCACTGTGACC-3’) upstream of the TATA box. This promoter drives the 
expression of an enhanced luciferase reporter gene sequence derived from 
Photinus pyralis. 
To perform the ER-CALUX assay, T47D.Luc cells were seeded with estrogen- and 
phenol red-free medium into 96 well plates at a density of 5’000 cells per well. The 
cells were exposed to the test compounds dissolved in DMSO resulting in a final 
DMSO concentration of 0.1%. After 24 hours, the medium was removed and the 
cells were lysed by addition of 100 µl of Lysis Buffer (Promega) and gentle 
shaking at room temperature for 10 minutes. Then the plates were assayed on a 
Dynex microplate luminometer for luciferase activity by automated addition of 
luciferin. Upon expression of the luciferase enzyme, luciferin is oxidised to 
oxyluciferin, thus generating photons that are detected in the luminometer. The 
reaction is as follows: 
 
 
 
 
 
The emitted light has a wavelength of 562 nm and is directly proportional to the 
amount of luciferase produced, thereby reflecting the estrogenicity of the tested 
compounds. A 17β-estradiol standard curve (10 pM, 30 pM, 60 pM, 100 pM) as 
well as negative (cells with medium only) and blank controls (medium only) were 
included on all plates to calibrate the estrogenicity of the test compounds. 
 
 
4.4  Isolation of total RNA 
 
After 24 hours exposure to the compounds, cells are harvested by trypsinisation as 
described in section 3.1. After centrifugation, the cell pellet is transferred to ice 
and the total RNA is extracted according to the QIAGEN® RNeasy protocol. This 
extraction method involves the denaturation of cellular proteins with guanidine-
thiocyanate, the precipitation of nucleic acids with ethanol and the selective 
binding of RNA to a silica-based membrane combined with high-speed 
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microcentrifugation. 
First, the cells and the membranes of their organelles are lysed with 600 µl of 
buffer RLT containing β-ME and guanidine-thiocyanate, which also inactivates  
RNase enzymes. The lysate is homgenised with QIAshredder spin columns that 
eliminate high molecular weight components like genomic DNA, only the eluate is 
collected and further processed. Subsequently, 600 µl ethanol are added to provide 
best binding conditions for RNA to the silica membrane in the RNeasy spin 
columns. The sample is transferred to an RNeasy spin column placed in a 2 ml 
collection tube and centrifuged for 15 seconds at ≥ 10’000 rpm. The eluate is 
discarded and the membrane is subjected to three washing steps: once with 700 µl 
of buffer RW1 (containing guanidine-thiocyanate) and twice with 500 µl of buffer 
RPE (containing ethanol). Next, the spin column is placed into a new collection 
tube and centrifuged for 1 minute to dry the silica membrane and prevent carry-
over of buffer into the total RNA eluate. The final elution is carried out into a new 
1.5 ml collection tube with 30 µl RNase-free water, loaded directly onto the 
membrane, by centrifugation for 1 minute at 10’000 rpm. The purified total RNA 
is stored at –20 °C. 
 
 
4.5 Quantification and quality control of total RNA 
 
The total RNA concentration is determined with a UV-spectrophotometer and the 
total RNA quality (integrity and size distribution of the total RNA) is assessed with 
the Agilent 2100 Bioanalyzer. 
 
UV-spectrophotometer: 
Due to the fact that nucleic acids have their absorbance maximum at 260 nm, the 
concentration of the extracted total RNA can be determined by UV-
spectrophotometry. The UV-spectrophotometer is calibrated wih 0.1 ml of Tris-
HCl buffer. Each total RNA sample is diluted 1 : 200 with 10 mM Tris-HCl buffer, 
pH = 7.0 (0.5 µl sample RNA in 99.5 µl buffer) and absorbance is measured at 
260/280 nm. An absorbance of 1 unit at 260 nm corresponds to 40 µg/ml of RNA. 
The RNA purity can be estimated by the ratio of the absorbance values at 260 nm 
and 280 nm (A260/A280), which should range from 1.8 to 2.1. 
 
Agilent 2100 Bioanalyzer: 
Total RNA samples consist by more than 80% of ribosomal RNA (rRNA) and only 
approximately 1-3% messanger RNA (mRNA). Therefore, a first quality 
assessment is based on the 28S : 18S ratio of rRNA. As the 28S and 18S rRNAs 
are approximately 5 kb and 2 kb in size, the theoretically possible ratio of 28S : 
18S is 2.7 : 1, but a ratio of 2 : 1 is considered as a marker for intact, poorly 
degraded RNA. In practice, values higher than 1.7 suggest high quality RNA. 
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The Agilent 2100 bioanalyzer is an on-chip electrophoresis (microchannels graved 
in glass) system and uses a combination of micro-fluidics, capillary electrophoresis 
and fluorescent dyes that bind to nucleic acid to simultaneously evaluate RNA 
concentration and integrity. The RNA-associated fluorescence is monitored as 
RNA molecules move through a detector along the separation channel of the chip, 
the RNA and the fluorescence of these molecules is measured as they pass the 
detector. The resulting data is translated into gel-like images and 
electropherograms, which are used for the 28S : 18S ratio calculation (Figure 5).  
 
 
Figure 5: high quality total RNA electropherogramme obtained in the Agilent 2100 
bioanalyzer 
 
 
4.6 Complementary DNA synthesis 
 
The GeneChip® One-Cycle cDNA Synthesis Kit and Poly–A RNA Control Kit are 
used for the conversion of mRNA to complementary DNA. The amount of total 
RNA used in each reaction is 5 µg. To have an endpoint control for the labelling 
process, exogenous positive controls in form of polyadenylated transcripts from 
Bacillus subtilis genes, which are absent in eukaryotic cells. These prokaryotic 
transcripts (lys, phe, thr, dap) are added to the RNA samples. Reaction mixtures 
containing total RNA (5 µg), 2 µl poly-A RNA control and 2 µl 50 µM T7-
oligo(dT) primer (sequence: 5'–GGCCAGGCGG–(dT)24–3'), were incubated in 
RNase-free water for 10 minutes at 70 °C, followed by cooling at 4 °C. Then the 
First-Strand Master Mix, consisting of 5x First-Strand Reaction Mix, 0.1 M DTT 
and 10 mM dNTPs, were added. After incubation at 42°C for 2 minutes, 1 µl 
SuperScript II (reverse transcriptase) was added and the tube was maintained at 
42°C for 1 hour, followed by a cooling to 4 °C. Thereafter, 130 µl of the Second-
Strand Master Mix (RNase-free water, 5x Second-Strand Reaction Mix, 10 mM 
dNTP, E. coli DNA ligase, E. coli DNA Polymerase I and RNase H) were added 
and the samples incubated for 2 hours at 16 °C. The reaction was supplemented 
with T4 DNA polymerase (2 µl) and incubated another 5 minutes at 16 °C. Then 
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10 µl 0.5 M EDTA are added and the samples were processed for complementary 
DNA purification. 
 
 
4.7 Cleanup of complementary DNA 
 
The GeneChip® Sample Cleanup kit is used to isolate the complementary DNA. 
For that purpose, 600 µl of cDNA Binding Buffer are added to the DNA 
preparation; 500 µl of the sample are applied onto a cDNA cleanup Spin Column, 
which is centrifuged at 10’000 rpm for 1 minute. The flow through is discarded, 
and the procedure repeated. The spin column is then transferred to a new collection 
tube and 750 µl of cDNA Wash Buffer are loaded onto the column, followed by 1 
minute centrifugation at ≥ 10’000 rpm. To dry the silica membrane, the spin 
columns are centrifuged with opened caps for 5 minutes at maximum speed 
(20’000 rpm). For elution, the columns are transferred into 1.5 ml-collection tubes 
and 14 µl of cDNA Elution Buffer are loaded directly onto the spin column 
membrane. After a 1-minute incubation at room temperature, the column is 
centrifuged at 20’000 rpm for 1 minute to elute the complementary DNA. 
 
 
4.8 Synthesis of biotin-labelled complementary RNA 
 
The GeneChip® IVT Labeling Kit is used for complementary RNA synthesis. For 
that purpose, the cDNA eluate (~ 12 µl) is transferred into RNase-free microfuge 
tubes and the following components are added: RNase-free water to a final volume 
of 40 µl, 4 µl 10x IVT Labelling Buffer (containing spermidine), 12 µl IVT 
Labelling NTP Mix (including a synthetic biotin-conjugated nucleotide analog) 
and 4 µl IVT Labeling Enzyme Mix (containing RNA-polymerases). The reagents 
are carefully mixed and briefly centrifuged prior to incubation at 37 °C for 16 
hours. 
 
 
4.9 Cleanup and quantification of the biotinylated complementary RNA 
 
The GeneChip® Sample Cleanup kit is used for purification of complementary 
RNA. Unincorporated NTPs are removed to guarantee an accurate determination 
of concentration and purity of the biotinylated cRNA. Sixty µl of RNase-free water 
are added to the complementary RNA and mixed by vortexing. Then, 350 µl IVT 
cRNA Binding Buffer are added, the sample is thoroughly mixed by vortexing. 
After adding 250 µl ethanol, the sample is applied to the IVT cRNA Cleanup spin 
 22 
column, which is centrifuged for 15 seconds at 10’000 rpm. The flow through is 
discarded and the spin column is transferred to a new 2-ml collection tube for 
washing with 500 µl of IVT cRNA Wash Buffer. Another 500 µl of ethanol (80%; 
v/v) are loaded and the spin column is centrifuged for 15 seconds at 10’000 rpm. 
The flow through is again discarded. Next, the spin column is centrifuged with 
open cap for 5 minutes at maximum speed (20’000 rpm) to allow for complete 
drying of the membrane. Finally, the spin column is transferred into a new 
collection tube and 11 µl of RNase-free water are loaded directly onto the 
membrane followed by a 1-minute centrifugation at maximum speed to elute the 
biotinylated complementary RNA. This procedure is repeated once. 
The complementary RNA is quantificated by UV spectrophotometry and the over-
all quality is assessed with the Agilent 2100 Bioanalyzer as described in 3.2. The 
total quantity of RNA is determined using the following equation. 
 
adjusted cRNA yield = RNAm – (total RNAi) x (y) 
 
 RNAm = amount of complementary RNA measured after IVT in µg 
 total RNAi = starting amount of total RNA in µg 
 y = fraction of complementary DNA used for the IVT reaction (12 µl) 
 
 
4.10 Fragmentation of the complementary RNA 
 
Fragmentation of complementary RNA is achieved by metal-induced hydrolytic 
breakdown to 35-200 base fragments). For that purpose, 20 µg of complementary 
RNA are mixed with 8 µl of 5x Fragmentation Buffer (from the GeneChip® 
Sample Cleanup kit and RNase-free water to a final volume of 40 µl. The 
fragmentation mixture is incubated for 35 minutes at 94 °C.  
 
 
4.11 Hybridisation on the probe array 
 
The GeneChip Hybridisation, Wash and Stain kit is used for this step, according to 
manufacturer’s instruction. The following components are used for the 
hybridisation cocktail: 5 µl Control Oligonucleotide B2 (3 nM) (used as a grid 
alignment reference), 15 µl 20x Prokaryotic Hybridisation Controls (bioB, bioC, 
bioD, cre), 150 µl 2x Hybridisation Mix, 3 µl herring sperm DNA (10 mg/ml), 3 µl 
BSA (50 mg/ml), 30 µl DMSO, 15 µg of the fragmented and labelled 
complementary RNA. The volume is adjusted to 300 µl with RNase-free water and 
the mixtures is heated to 99°C for 5 minutes. 
The probe arrays are wetted with 200 µl of 1x Hybridisation Buffer and incubated 
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for 10 minutes at 45°C in the hybridisation oven shaking at 60 rpm. The 
Hybridisation mixture is incubated for 5 minutes at 45°C and clarified by 
centrifugation (20’000 rpm). Then the Hybridisation Buffer is removed from the 
probe arrays and replaced by 200 µl of the hybridisation mixture. The probe arrays 
are hybridised for 16 hours at 4 °C in the oven shaking at 60 rpm. 
 
 
4.12 Washing, staining and data acquisition 
 
After 16 hours of hybridisation, the cocktail is removed and the arrays are washed 
following the manufacturer’s instructions in the Fluidics Station 400. For staining, 
the SAPE and antibody solutions are prepared as follows: 
 
SAPE solution 
600 µl 2x Stain Buffer, 48 µl 50 mg/ml BSA, 12 µl 1 mg/ml streptavidin 
phycoerythrin (SAPE) and 540 µl DEPC-treated H2O are mixed and divided into 
two aliquots of 600 µl each. The SAPE solution has to be protected from light. 
 
Antibody solution  
300 µl 2x Stain Buffer, 24 µl 50 mg/ml BSA, 6 µl 10 mg/ml Goat IgG, 3.6 µl 0.5 
mg/ml biotinylated antibody (anti-streptavidin) and H2O to a final volume of 
600 µl. 
 
After inserting the probe arrays into their designated module of the Fluidics Station 
400, the tubes are placed into the appropriate sample holders of each module (two 
times 600 µl SAPE solution and one 600 µl antibody solution per module). When 
washing and staining of the arrays is completed, the probe arrays are checked for 
large air bubbles that might constrain the scanning, the glass surfaces of the probe 
arrays are gently cleaned with a non-abrasive towel and, to prevent leakage of 
fluids (Wash Buffer A), the separations of the probe array cartridges are sealed 
with Tough Spots. Then the probe array cartridges are inserted in the scanning 
revolver of the GeneChip® Scanner 3000 and scanning of the arrays is performed 
at a pixel value of 3 µm and 570 nm wavelength. The scanner is controlled by 
GCOS (Gene Chip Operating Software). 
 
 
4.13  Data analysis 
 
Microarray quality assessment, condensing of the probe sets, data normalization 
and filtering were conducted using the Expressionist software (Genedata AG, 
Basel, Switzerland). T-tests were performed between controls and treated cells to 
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assess the statistical significance of differentially expressed genes. False discovery 
rates were determined according to Benjamini-Hochberg (1995). Finally, the 
means of 3-5 replicates were imported into a Microsoft Excel file for graphical 
representation and determination of correlation coefficients. The “Gene Ontology” 
database (www.geneontology.org) was consulted for the molecular function of 
each transcript and only gene products with a known or inferred function are 
displayed in the figures.  
 
 
4.14  Extraction and analysis of the milk samples 
 
The sample preparation procedure developed for extracting phytoestrogens from 
milk, including the removal of endogenous estrogen hormones, has been adopted 
from Courant et al. (2007). Briefly, samples (cow milk or soymilk obtained from a 
local retailer) were extracted in 10 ml aliquots with acetate buffer (2 M, pH 5.2) 
and acetone. After centrifugation, the supernatants were collected and the acetone 
phase was evaporated under a nitrogen stream. Subsequently, an enzymatic 
hydrolysis was carried out by overnight incubation (52º C) with a purified Helix 
pomatia preparation (Sigma, St. Louis, MO, USA). This deconjugation step was 
followed by purification through two successive cartridges combining a reverse 
(C18) and a normal (silica) stationary phase (SDS, Peypin, France). After 
evaporation of the methanol eluate, the remaining residues were reconstituted in 
30 µl of dimethyl sulfoxide (DMSO) for the cell culture experiments. Separate cow 
milk and soymilk samples were subjected to the same procedure, except that a 
deuterated compound (daidzein-d3) was included as internal standard. These 
samples were analyzed by liquid chromatography-tandem mass spectrometry for 
the quantitative determination of phytoestrogens (Antignac et al. 2003). The 17β-
estradiol measurements were performed according to a previously described 
method (Courant et al. 2007). 
 
 
4.15 Real-time RT-PCR 
 
PCR quantifications were carried out to validate the microarray hybridization 
results. Primers for the selected transcripts were obtained from Applied 
Biosystems. Briefly, 100 ng of complementary DNA were mixed with 100 nM of 
forward and reverse primers in a final volume of 25 µl. The reactions were 
performed in an ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems) for 45 cycles (95 ºC for 15 sec, 60 ºC for 1 min) after an initial 
incubation time of 10 minutes at 95ºC. The fold change in the expression of each 
gene was calculated using the 2-∆∆CT method (Livak and Schmittgen, 2001), with 
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the abundant glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript as 
an endogenous control. 
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5.  Results 
 
5.1 Sample preparation and analysis 
 
After liquid extraction and enzymatic deconjugation, the soy and cow milk 
samples (10 ml each) were subjected to a two-step fractionation procedure using 
reverse phase (C18) and normal phase (silica) cartridges. The quantitative analysis 
by liquid chromatography coupled to tandem mass spectrometry confirmed that 
soymilk contains large quantities of the isoflavones genistein and daidzein, 
whereas cow milk is characterized by the presence of low levels of enterolactone 
together with trace amounts of other phytoestrogens (Table 2). Additional 
measurements by gas chromatography-mass spectrometry verified that endogenous 
estrogen hormones, including 17β-estradiol, were removed from the cow milk 
sample during the final solid-phase extraction step. For the subsequence cell 
culture experiments, each isolate from a 10 ml sample was reconstituted in 30 µl 
dimethyl sulfoxide (DMSO), which proved to be compatible with the solubility 
properties of the various phytoestrogens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: 
Concentrations (ng/ml) determined for the target phytoestrogens in the analysed 
soymilk and cow milk samples (nd, not detected at the limit of detection, which 
varied from 0.05 to 0.7 ng/ ml depending on the compound) 
Concentration 
(ng/ ml) Compound 
Soy milk Cow milk 
Daidzein 1233 8.3 
Genistein 5175 5.6 
Equol nd 2.6 
Formononetin 9.6 1.8 
Biochanin A nd nd 
Glycitein 98.5 nd 
Enterolactone 1.1 5.2 
Matairesinol nd nd 
Coumestrol nd nd 
Resveratrol nd nd 
 27 
5.2 Cell viability assay, ER-CALUX 
 
For the cell viability assay, human MCF-7/BUS and T47D breast cancer cells were 
initially exposed to increasing concentrations of the soy and cow milk extracts 
dissolved in DMSO (0.05%, 0.1% and 0.3% (v/v)) or the same amounts of DMSO 
alone. Cell viability was tested 24 hours later with the AlamarBlue® TM 
cytotoxicity assay by measuring the intracellular mitochondrial activity, which is 
used as an indicator of metabolic activity. The resulting dose responses 
demonstrated that no cytotoxic reactions were triggered when the cell culture 
medium contained up to 0.3% of milk extract dissolved in DMSO.  
Next, the soy and cow milk extracts were tested for their overall estrogenic activity 
using a standard reporter gene assay, i.e., the ER-CALUX assay. For that purpose, 
we exploited a stably transfected carcinoma cell line (T47D.Luc) that carries a 
chromosomally integrated reporter gene sequence (Legler et al., 1999). This 
artificial construct drives the expression of firefly luciferase in response to ER 
activation and ER binding to the ERE. Thus, to monitor estrogenic activity, cell 
lysates were examined for luciferase activity after a 24-h treatment with 
progressively increasing concentrations of 17β-estradiol and the different extracts 
added to the cell culture medium. In all treatments, the final concentration of the 
DMSO solvent was set to 0.1%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Luciferase reporter gene assay (ER-CALUX) 
T47D.Luc cells were incubated with 17β-estradiol (E2, at concentrations of 1-100 
pM), as well as soy or cow milk extracts. The final concentration of the DMSO 
solvent was 0.1%. ER activation was determined by measuring the luciferase 
induction from a minimal promoter containing repeats of EREs (mean values of 5-
6 independent experiments). The results are shown in percentages of the induction 
observed with 60 pM 17β-estradiol. 
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In a series of control reactions, the synthetic promoter mediated a dose-dependent 
luciferase induction in response to the 17β-estradiol standard. This estrogenic 
effect reached peak levels at a hormone concentration of 60 pM (Fig. 6). A similar 
level of reporter gene induction was observed in the cells incubated with soymilk 
extract. The corresponding cow milk extract resulted in a considerably lower 
reporter gene induction compared to the soymilk extract, which is, however, in 
agreement with its marginal phytoestrogen content (Fig. 6). These responses to the 
treatment with 17β-estradiol or soymilk extract were completely suppressed by the 
addition of the ER antagonist ICI 182,780 at a concentration of 0.1 µM. 
 
 
5.3 Expression profiles induced by soy and cow milk samples 
 
The MCF7/BUS breast cancer cell line is markedly more responsive to estrogenic 
stimuli than T47D cells, thus delivering a wider range of estrogen-regulated genes 
as well as larger amplitudes of expression changes (Buterin et al., 2006). 
Therefore, MCF7/BUS cells were used to perform genome-wide analyses of 
endogenous transcripts after a treatment with phytoestrogen mixtures reconstituted 
in culture medium. The target cells were incubated in triplicates with soymilk or 
cow milk extracts to reach a final solvent concentration of 0.1% (v/v). After 24-h 
exposure times, a fraction of RNA from each sample was analysed using 
Affymetrix microarrays that display the sequences of 47’400 human transcripts. To 
identify genes that are susceptible to ER regulation, these microarray data were 
normalized and subjected to statistical analysis. Also, in view of the large number 
of regulated genes, the expression data were filtered for transcripts that exhibited at 
least a fivefold change relative to the solvent control, thereby eliminating the vast 
majority of gene products that are more moderately affected or not altered at all 
following the phytoestrogen treatment. The significance threshold was P < 0.01, 
yielding false discovery rates in the range of 0.02 - 0.1 (Benjamini & Hochberg, 
1995).  
The incubation with the soymilk extract resulted in a total of 358 different 
transcripts that were at least fivefold up- or down-regulated compared to the 
solvent control group. In contrast, the gene expression profile induced by the cow 
milk sample deviated only marginally from the background transcriptional pattern 
observed in the solvent control group. In this case, only six transcripts were 
affected by more than fivefold changes, thus reflecting the much lower 
phytoestrogen concentration and content in cow milk. 
The transcripts displaying the highest amplitude of regulation in response to the 
treatment with soymilk phytoestrogens are shown in Figure 7. The majority of 
these transcripts encode for proteins involved in DNA metabolism (RRM2, TYMS, 
TK1; see legend to Fig. 7 for abbreviations), DNA replication or recombination 
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(MCM10, CDT1, TOP2A, PRIM1, RAD51), cell division cycle (CCNA2, CDC2, 
CDC6, TTK), chromosome segregation and centromere function (AURKB, 
KNSL7, Spc24, Spc25, CDCA1, KNTC2, KIF2C, ESPL1, ASPM) or inhibition of 
apoptosis (BIRC5). Together with the overexpressed proto-oncogenes MYBL1 and 
MYBL2 as well as two different proliferation markers (MKI67 and OIP5), this 
transcriptional profile reflects the typical mitotic signature observed in estrogen-
stimulated breast cancer cells (Lobenhofer et al., 2002; Coser et al., 2003; Frasor 
et al., 2003; Vendrell et al., 2004; Buterin et al., 2006; Lavigne et al., 2007). 
When the expression changes resulting from the soymilk extract exposure where 
juxtaposed to the expression changes induced by the 17β-estradiol treatment, their 
striking similarity became apparent. In fact, all transcripts that were increased by 
incubation with the soymilk extract were also up-regulated following the treatment 
with 17β-estradiol (Fig. 8). To analyse this presumed relationship in more 
quantitative terms, the messenger RNA profile induced by the soymilk extract was 
plotted against the corresponding values obtained with 17β-estradiol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  
Comparison of genome-wide transcriptional changes in MCF-7/BUS cells exposed 
to soy and cow milk extracts or 17β-estradiol. Transcripts with the highest 
amplitude of induction following a treatment with 0.1 % soymilk extract in 
comparison to the level of the same transcripts following the treatment with cow 
milk and 30 pM 17β-estradiol. 
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Abbreviations in Figure 7: RRM2, ribonucleotide reductase M2; AURKB, aurora 
kinase B; MCM10, minichromosome maintenance-deficient 10; TYMS, 
thymidylate synthetase; CCNA2, cyclin A2; KNSL7, kinesin-like 7; Spc25, 
kinetochore protein Spc25; UHRF1, ubiquitin-like, containing PHD and RING 
finger domains 1; TK1, thymidine kinase 1; FOXM1, forkhead box 1; GAJ, GAJ 
protein; MYBL1, myeloblastosis oncogene-like 1; MYBL2, myeloblastosis 
oncogene-like 2; TOPK, T-LAK cell-originated protein kinase; FKSG14, leucine 
zipper protein FKSG14; KNTC2, kinetochore associated 2; CDC2, cell division 
cycle 2; CDT1, DNA replication factor; TOP2A, topoisomerase II-α; CDC6, cell 
division cycle 6; KLIP1, KSHV latent nuclear antigen interacting protein 1; 
TMPRSS3, transmembrane protease serine 3; MKI67, antigen identified by 
monoclonal antibody Ki-67; DLG7, discs large homolog 7; Spc24, kinetochore 
protein Spc24; OIP5, Opa-interacting protein 5; NUSAP1, nucleolar and spindle-
associated protein 1; CDCA1, cell division cycle-associated 1; BIRC5, baculoviral 
IAP repeat-containing 5; ANLN, anilin; BRRN1, barren homolog; PRO2000, 
PRO2000 protein; KIF2C, kinesin family member 2C; PRIM1, primase 1; ESPL1, 
extra spindle poles-like 1; ASPM, abnormal spindle-like microcephaly; TTK, TTK 
protein kinase; RAD51, RAD51 homolog; TCF19, transcription factor 19; 
SHCBP1, ortholog of mouse Shc SH2-domain binding protein 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: 
Linear regression analysis of pairs of data obtained with 0.1 % soymilk extract 
and 30 pM 17β-estradiol. A fivefold change (up- or down-regulation) in the 
soymilk-treated samples relative to the controls was used as the cut-off to filter the 
data. A total of 358 transcripts passed the statistical threshold of P < 0.01. 
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All transcripts that showed at least a fivefold up- or down-regulation in the 
phytoestrogen treatment group were included in this analysis. The general 
threshold for statistical significance was P < 0.01. Figure 8 shows that the data 
points in this comparison grouped in two distinct clusters reflecting those genes 
that were over-expressed and those that were under-expressed relative to the 
solvent control group. A linear regression analysis of all 358 pairs of data yielded 
an overall correlation coefficient of R = 0.87, thereby exceeding the values (R ≈ 
0.6) found in another similar study that compared expression changes induced by 
soy extracts with those resulting from 17β-estradiol exposure (Ise et al., 2005). 
The close correspondence of expression values, demonstrated in Figure 8, is 
supporting the notion that soy phytoestrogens and 17β-estradiol induce nearly 
identical transcriptional responses in MCF7/BUS cells. Thus, in contrast to 
previous reports (Wang et al., 2004; Ise et al., 2005), we found that the 
transcriptional machinery of this breast cancer cell line responds in a very similar 
manner to different estrogenic stimuli. 
 
5.4 Real-time PCR: Validation of microarray results 
 
Real-time reverse transcriptase-PCR (RT-PCR) assays were carried out on 
representative sequences to confirm the tight correlation between the expression 
profiles induced by soy phytoestrogens and 17β-estradiol. The following 
transcripts were tested subsequent to treatment with either soymilk phytoestrogens 
or the physiologic hormone 17β-estradiol: RRM2 (ribonucleotide reductase M2 
polypeptide), CDC2 (cell division cycle 2), TTK (a protein kinase) and UAGT5 
(UDP-N-acetylglucosaminyltransferase 5). 
The exposure to soy phytoestrogens was performed with three different 
proportions of extract in the cell culture medium, between 0.001% and 0.1% (v/v). 
In view of the phytoestrogen contents listed in Table 2, these soymilk residues 
translate to genistein concentrations ranging from 0.1 to 10 µM. Incubations with 
the 17β-estradiol reference were performed using the standard concentration of 30 
pM. After normalization with the constitutive GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) transcript, expression values were transformed as the 
ratio of messenger levels between treated cells and solvent controls. A linear 
regression analysis of the resulting RT-PCR values yielded higher correlation 
coefficients of R = 0.92 – 0.98, thus confirming a tight correlation between the 
transcriptional changes induced by soy phytoestrogens and the physiologic 
estradiol hormone (Figure 9).  
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Figure 9: 
RT-PCR analysis of selected transcripts that were regulated following exposure of 
MCF7/BUS cells to estrogenic stimuli. The results obtained with three different 
concentrations of the soymilk extract (0.001%, 0.01%, 0.1%; v/v) were plotted 
against the corresponding values obtained in the experiment with 17β-estradiol 
(30 pM). The fold changes were measured using the GAPDH transcript as an 
endogenous control (mean values of 4 – 5 independent determinations). The linear 
regression analysis to determine the degree of similarity between the 
transcriptional changes induced by soymilk extract and 17β-estradiol yielded 
correlation coefficients of R = 0.92 – 0.98. 
 
 
5.5 Expression profiles induced by single phytoestrogens 
 
Buterin et al., 2006 demonstrated that genistein, the predominant soy 
phytoestrogen, induces global gene expression profiles in both MCF7/BUS and 
T47D cells that are indistinguishable from the transcriptional changes resulting 
from 17β-estradiol treatments. A similar convergence was now obtained when we 
assessed the response of MCF7/BUS cells to daidzein, another major soy 
phytoestrogen, tested at a concentration of 1 µM (Fig. 10-1). Subsequently, this 
study was extended to different categories of phytoestrogens including coumestrol, 
resveratrol and enterolactone. The specific criteria for inclusion of the transcripts 
into the correlation analyses of Figure 10 were again a fold change greater than 5 
and a corresponding P value less than 0.01. Compared to the daidzein treatment, 
the number of significantly regulated transcripts was slightly higher in the 
coumestrol experiment (Figure 10-2) and markedly reduced in the resveratrol and 
enterolactone treatments (Figures 10-3 and 10-4). However, a direct comparison 
with the effects of 17β-estradiol on the same human genes yielded correlation 
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coefficients of R = 0.85 – 0.92, further supporting the idea that, at least in a low-
dose range, all kinds of phytoestrogens generate expression profiles in human 
breast cancer cells that are identical to the transcriptional pattern elicited by a 17β-
estradiol stimulus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: 
Comparison between 17β-estradiol and single phytoestrogens treatment.  
MCF7/BUS cells were incubated with 1 µM of the indicated phytochemicals (3 - 4 
independent replicates). The resulting expression changes were plotted against the 
corresponding data obtained with 17β-estradiol (30 pM). A fivefold change in the 
phytoestrogen-treated samples was used as the cut-off to filter the data, and the 
number of significantly (P < 0.01) regulated transcripts is indicated for each 
compound. The quantitative relationship between the different molecular 
fingerprints was determined by linear regression analyses, yielding correlation 
coefficients of R = 0.85 - 0.92 
 
 
 
1 
3 4 
2 
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5.6 Influence of ERβ  on expression profiles 
 
RT-PCR quantifications with oligonucleotide primers specific for each ER subtype 
showed that the predominant mRNA in MCF7/BUS and T47D cells is the one 
coding for ERα, whereas ERβ transcripts remained undetectable (data not shown). 
These findings are consistent with previous studies reporting the presence of only 
trace amounts of ERβ transcripts in T47D cells and essentially no such transcripts 
in MCF7/BUS cells (Legler et al., 1999; Lobenhofer et al., 2002). By 
immunoblotting methods it has also been shown that there is no detectable ERβ 
protein in T47D cells (Ström et al., 2004). The lack of an appropriate breast cancer 
cell line containing significant amounts of ERβ protein can be circumvented by 
taking advantage of a genetically modified cell line (T47D-ERβ) in which a 
tetracycline-regulated construct drives the expression of a full-length human ERβ 
sequence (Ström et al., 2004; Matthews, 2006). We used this stably transfected 
T47D-ERβ cell line to examine the contribution of ERβ to the transcriptional 
reprogramming triggered by phytoestrogens. 
T47D-ERβ cells were exposed to 1 µM coumestrol because this particular 
phytochemical displays the highest affinity for ERβ among all phytoestrogens 
tested to date (Kuiper et al. 1997; Kuiper et al. 1998; Bovee et al., 2004; Mueller et 
al., 2004). The transcriptional variances following this coumestrol treatment were 
scrutinised in the presence of tetracycline, i.e. under conditions that suppress the 
expression of ERβ, as well as after tetracycline withdrawal, resulting in promoter 
activation and ERβ co-expression. In the absence of tetracycline, the level of 
messenger RNA coding for ERβ is 4 – 5 times higher than that of the 
corresponding ERα transcripts (Ström et al., 2004), hence confirming that this 
inducible system leads to expression of both receptor subtypes in substantial 
quantities. To eliminate possible confounding effects due to the antibiotic used for 
ERβ suppression, the fingerprints obtained in the presence of tetracycline were 
compared to appropriate solvent controls containing the same concentration of 
antibiotic. Conversely, the fingerprints obtained after tetracycline withdrawal, 
consequently leading to ERβ expression, were determined against corresponding 
controls without tetracycline in the medium. 
The distinctly different gene expression profiles induced by coumestrol in the 
absence or in the presence of ERβ are illustrated in Figure 11. To simplify the 
representation of data, the graph of Figure 11 shows only those transcripts that 
were up-regulated by a fold change greater than 10 in at least one of the treatment 
groups (P < 0.01 for all transcripts). The response obtained in T47D-ERβ cells 
containing ERα alone involves for example an overexpression of IL20 (see legend 
to Figure 11 for abbreviations), CXCL2, IGFBP4, MYB or TFF1 (also known as 
pS2). The range of regulated target genes did not change when, in the absence of 
tetracycline, both ERα and ERβ were expressed concomitantly in the same cell 
line. However, the induction of many transcripts was attenuated in the presence of 
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ERβ, indicating that this additional receptor subtype is able to partially suppress 
the transactivation functions exerted by ERα. Conversely, in the presence of ERβ, 
other transcripts were regulated with larger amplitudes of induction than in the 
cells expressing ERα only. This second category of genes, which become more 
responsive in the presence of ERβ, include for example tripin, TOP2A (see legend 
to Figure 10 for abbreviations), the cyclin-dependent kinase inhibitors CDKN3 and 
CDKN2C as well as multiple members of the kinesin family (KNSL7, KIF20A, 
KIF14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: 
Impact of ERβ on gene expression profiles. T47D-ERβ cells were exposed to 1 µM 
coumestrol either in the presence or in the absence of tetracycline. The fold 
changes of each transcript (mean values of three independent experiments) were 
calculated using, as the reference, solvent controls with or without tetracycline. 
Light grey: gene expression profile in cells containing only ERα (in the presence 
of tetracycline). Dark grey: gene expression profile induced in cells containing 
both ERα and ERβ (in the absence of tetracycline). 
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Abbreviations in Figure 11: IL20, interleukin 20; PDLIM3, PDZ and LIM domain 
3; DHRS2, dehydrogenase/reductase (SDR family) member 2; CXCL12, 
chemokine ligand 12; FABP5, fatty acid binding protein 5; KCNK5, potassium 
channel, subfamily K, member 5; IGFBP4, insulin-like growth factor binding 
protein 4; MYB, myeloblastosis oncogene; TMPRSS3, transmembrane protease 
serine 3; IRS1, insulin receptor substrate 1; ST8SIA-VI, alpha 2,8-
sialyltransferase; RASGRP1, RAS guanyl releasing protein 1; NPY1R, 
neuropeptide Y receptor 1; RERG, RAS-like estrogen-regulated growth inhibitor; 
PIF1, DNA helicase homolog 1; BIN3, bridging integrator 3; TFF1, pS2, trefoil 
factor 1; GAL, galanin; PLK1, polo-like kinase 1; TOSO, regulator of Fas-
induced apoptosis; PDZK1, PDZ domain containing 1; ASPM, abnormal spindle-
like microcephaly; SLC26A2, solute carrier family 26 member 2; ADRA2A, 
adrenergic alpha-2A receptor; STC2, stanniocalcin 2; MYC, myelocytomatosis 
oncogene; GPSM2, G-protein signaling modulator 2; CENPF, centromere protein 
F; CDKN3, cycline-dependent kinase inhibitor 3; IL17RB, interleukin 17 receptor 
B; ANLN, anilin; NUSAP1, nucleolar and spindle-associated protein 1; ANP32E, 
acidic nuclear phosphoprotein 32 family E; RACBAP1, Rac GTPase activating 
protein 1; STK6, serine-threonine kinase 6; KIF18A, kinesin family member 18A; 
MCLC, Mid 1-related chloride channel 1; GTSE1, G2 and S phase-expressed 1; 
HMGB2, high-mobility group box 2; CDKN2C, cyclin-dependent kinase inhibitor 
2C; HCAP-G, chromosome condensation protein G; TRAF4, TRAF4-associated 
factor 1; PKIB, protein kinase inhibitor beta; CTNNAL1, catenin alpha-like 1; 
CDCA3, cell division cycle-associated 3; MKI67, antigen identified by 
monoclonal antibody Ki-67; Spc25, kinetochore protein Spc25; CCNA2, cyclin 
A2; TOP2A, topoisomerase II-α; NEK2, never in mitosis gene a-related kinase 2; 
PMSCL1, polymiositis-skleroderma autoantigen 1; HMMR, hyaluron-mediated 
motility receptor; FHL1, four and a half LIM domains 1; KNSL7, kinesin-like 2; 
XTP1, HBxAG transactivated protein 1; DEPDC1, DEP domain containing 1; 
KIF20A, kinesin family member 20A; KIF14, kinesin family member 14; GREB1, 
GREB1 protein. 
 
As many phytoestrogens display a selective binding affinity for ERβ whereas 17β-
estradiol has approximately the same affinity for both major estrogen receptor 
subtypes, ERα and ERβ, respectively (Kuiper et al., 1997; Kuiper et al., 1998), we 
next explored the hypothesis that the preferential interaction of these 
phytochemicals with ERβ may mediate a more distinctive transactivation function. 
These experiments were again carried out with coumestrol as this compound 
displays the highest affinity for ERβ among all tested phytoestrogens (Bovee et al., 
2004, Mueller et al., 2006). The resulting expression changes were filtered for 
transcripts that exhibit at least a threefold induction relative to the untreated 
controls. A statistical threshold of P less than 0.05 was applied to the differentially 
expressed transcripts. In T47D-ERβ cells expressing only ERα, in the presence of 
tetracycline, we observed the already known tight correlation between the 
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expression profiles generated by 17β-estradiol and coumestrol, with 79 transcripts 
matching the filtering criteria (Figure 12-1). In fact, upon linear regression 
analysis, the correlation coefficient between the 17β-estradiol and coumestrol data 
reached a value of R = 0.90. For the same transcripts, this correlation coefficient 
was reduced to R = 0.70 when the cells, in the absence of tetracycline, were 
expressing the ERβ subtype (Figure 12-2). Also, the slope of the linear regression 
decreased from 0.7 (Figure 12-1) to 0.3 (Figure 12-2), reflecting a diminished 
response to 17β-estradiol, relative to the effects of coumestrol, in cells expressing 
the ERβ subtype. Accordingly, the similarity of transcriptomic patterns generated 
by 17β-estradiol and coumestrol is reduced in the presence of ERβ, suggesting that 
this particular receptor subtype may indeed mediate differential cellular reactions 
upon stimulation by phytoestrogens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: 
Diverging expression profiles in the presence of ERβ. T47D-ERβ cells were 
challenged with 17β-estradiol (30 pM) or coumestrol (1 µM), either in the 
presence or in the absence of tetracycline. The fold changes of each transcript 
(mean values of three independent experiments) have been calculated using, as the 
reference, solvent controls with or without tetracycline. (1) Comparison of gene 
expression profile in cells containing only ERα (in the presence of tetracycline). 
(2) Comparison of expression profiles in cells containing both ERα and ERβ (in 
the absence of tetracycline).  These graphs illustrate that ERβ decreases both the 
correlation coefficient and the slope of the linear regression. 
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6.  Discussion 
 
Breast cancer has become the most common malignancy among American and 
European women (Rice & Whitehead, 2006). However, in Eastern countries such 
as Japan the incidence of breast cancer is only about one-third of that of Western 
populations. This difference has often been attributed to a much higher dietary 
intake of soy phytoestrogens (Konstantakopoulos et al., 2006; Martinez et al., 
2006; McCarty, 2006; Messina et al., 2006). Unfortunately, despite the large 
amount of research conducted in the last years, no clear consensus has emerged 
regarding the preventive action of phytoestrogens against cancer. There is still no 
conclusive evidence that the ingestion of phytoestrogens is directly related to a 
reduced incidence of breast cancer, or whether phytoestrogens rather represent a 
biomarker of generally healthy diets (Martinez et al., 2006; Rice & Whitehead 
2006). 
At low physiologic serum concentrations that are normally achieved by nutritional 
intake, phytoestrogens are likely to act through modulation of estrogen signaling. 
In fact, these observed serum concentrations (in the nM range) appear insufficient 
to inhibit tyrosine kinases or other enzymes that may provide alternative targets of 
phytoestrogen effects (McCarty, 2006). This low-dose estrogenic response is 
mediated by two members of the nuclear steroid receptor superfamily, ERα and 
ERβ. Both receptors constitute ligand-stimulated transcription factors that 
associate with co-regulatory partners to remodel chromatin and recruit the general 
transcription machinery to downstream genes (Katzenellenbogen & 
Katzenellenbogen, 2000; Hall et al., 2001; Moggs and Orphanides, 2001; Safe, 
2001). Although both receptors bind to the same consensus estrogen responsive 
element within gene promoters, ERα and ERβ have been shown to exert partially 
antagonistic effects (Omoto et al., 2003; Ström et al., 2004). 
Several findings converge on the idea that the proliferative stimulus on estrogen-
dependent tissues, mediated by activation of ERα, can be opposed by the 
expression of ERβ. First, transgenic mice lacking ERβ are more susceptible than 
wild-type controls to develop markers of epithelial hyperplasia in the mammary 
gland (Förster et al., 2002). Second, it has been observed that the mRNA coding 
for ERα is up-regulated during cancer progression, whereas the ERβ transcript is 
reduced in part via promoter methylation (Iwao et al., 2000; et al., 2000; Rody et 
al., 2005; Park et al., 2006). Third, the continued expression of ERβ in breast 
tumors is associated with low aggressiveness and improved survival rates 
compared to ERβ-negative counterparts (Hopp et al., 2004). Fourth, activation of 
ERα promotes the growth of breast cancer cells both in culture and in animal 
models (Soto et al., 1995; Hsieh et al., 1998; Allred et al., 2001; Ju et al., 2006) 
but, when ERβ is restored using an appropriate expression vector, it exerts a 
negative effect on cell proliferation or even induces apoptosis (Omoto et al., 2003; 
Skliris et al., 2003; Ström et al., 2004). This anti-proliferative action of ERβ 
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correlates with the down-regulation of several factors involved in DNA replication 
and the cell cycle machinery (Lin et al., 2007). 
Contrary to 17β-estradiol, which does not discriminate between ERα and ERβ, 
phytoestrogens bind to ERβ with up to five times higher affinities compared to 
ERα (Kuiper et al., 1997; Kuiper et al., 1998). This finding appears relevant in 
view of the possible action of ERβ as a tumor suppressor because phytoestrogens 
may be able to trigger beneficial responses through their preferential interaction 
with the ERβ subtype. In contrast, such a protective effect is abrogated in cells that 
specialize on the expression of ERα with minimal residual amounts of ERβ (Park 
et al., 2006). This possible mechanism was supported when, in the present work, 
we analyzed the transcriptional fingerprints induced by soymilk extracts in human 
breast cancer cells. This type of soy product has been tested in the context of our 
study because of its high content in isoflavones with estrogenic activity, such that 
the findings may be extrapolated to a wide range of other soy-based foods and 
supplements. Unlike previous reports (Wang et al., 2004; Ise et al., 2005), we 
observed that such a natural mixture of soy phytoestrogens, as well as other types 
of phytoestrogens, induce a stereotyped expression fingerprint in breast cancer 
cells containing high levels of ERα but essentially no ERβ. Thus, in the absence of 
ERβ, all tested phytoestrogens result in essentially the same expression changes as 
those induced by the endogenous 17β-estradiol, and this recurrent genomic profile 
reflects the proliferative response mediated through ERα activation. This particular 
signature includes the up-regulation of many factors involved in cell cycle, DNA 
replication, chromosome segregation and inhibition of apoptosis. However, when 
the expression of ERβ is reconstituted using an inducible genetic system, the same 
breast cancer cells react in a different manner to phytoestrogen stimulation. First, 
the induction of many growth-promoting transcripts involved in the cell division 
cycle is attenuated compared to the genuine 17β-estradiol response and, second, 
there is a stronger induction of factors that arrest cell proliferation, such as for 
example inhibitors of cyclin-dependent kinases, thus further contributing to the 
inhibition of cell proliferation. 
This mitigation of ERα-induced expression fingerprints may account for the 
presumed chemopreventive activity of phytoestrogens since, as indicated before, 
many of these compounds display particularly strong affinities for ERβ. In view of 
our findings, we propose a biphasic activity of phytoestrogens during cancer 
development in estrogen-sensitive tissues. Accordingly, the presumed beneficial 
effects of phytoestrogens depend on the timing of exposure. Normally, 
phytoestrogens are able to slow down cell growth by activating ERβ, thereby 
generating an anti-proliferative expression signature. Due to the genetic instability 
of malignant tumor cells, however, the expression of ERβ may be abrogated by 
gene deletion or promoter methylation. In such late-stage cancer cells, 
phytoestrogens, in conjunction with other estrogenic chemicals, induce a 
transcriptional profile that promotes the proliferation of those clones that exhibit 
high amounts of ERα but little ERβ. Thus, in the early stage of carcinogenesis 
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(with intact ERβ expression) phytoestrogen intake is more likely to exert 
beneficiary effects than in the later, ERα-dominated phases (Park et al., 2006). As 
binding of phytoestrogens to the ERβ results in an increased transcription of genes 
related to cell-cycle arrest, the proliferative effects exerted through ERα could 
possibly be opposed by ERβ and tumor growth might come to cessation. In light of 
these considerations, the potentially beneficial effect of phytoestrogens should be 
re-evaluated, particularly in relation to risk groups (for example postmenopausal 
women) who are susceptible to the development of ERα-positive but ERβ-negative 
tumors arising from steroid hormone-dependent tissues (Cassidy, 2003). 
Beyond the scope of this study, attentiveness should also be paid to another 
vulnerable risk group: newborns and infants. Although in most European countries 
the feeding of soy formula milk is restricted to infants with intolerance to regular 
formula, in the USA up to 36% of all formula-fed infants receive soymilk (Chen et 
al., 2004; Tan et al., 2006; Bernbaum et al., 2007; Cao et al., 2009). These 
children display plasma levels of isoflavones that are up to 200-fold higher than 
those of infants fed cow milk formula or human breast milk. The increased 
isoflavone levels were found to be higher than those that are thought to exert 
physiological effects in adults (Chen et al., 2004). Critical targets for adverse 
isoflavone effects in newborns and infants are ER-expressing cells in the 
gastrointestinal tract and in the central nervous system (Burton et al., 2002; Yellayi 
et al., 2002; Patisaul, 2005; Tan. et al., 2006; Bernbaum et al., 2008; Antignac et 
al., 2008). 
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7.  Abbreviations 
 
β-ME    =  β-Mercaptoethanol 
cDNA    =  Complementary DNA 
Coum    =  Coumestrol 
Daid     =  Daidzein 
DBD    =  DNA-binding domain 
DMEM   =  Dulbecco´s modified Eagle medium 
DMSO    =  Dimethylsulfoxide 
DNA    =  Desoxyribonucleic acid 
dNTPs             =      Deoxyribonucleotide triphosphates 
ds      =  Double-stranded 
DTT                 =      Dithiothreitol 
E2      =  17β-Estradiol 
Ent     =  Enterolactone 
ERα     =  Estrogen Receptor α  
ERβ     =  Estrogen Receptor β  
ERE     =  Estrogen Response Element 
FBS     =  fetal bovine serum 
H2O2    =  hydrogen peroxide 
ICI 182,780  =  Fulvestrant, steroidal antiestrogen 
IVT     =  in vitro transcription 
MCF-7 /BUS =  female mamma carcinome cell line, strain 7, subtype BUS,   
mRNA    =  messenger RNA 
PBS     =  Phosphate-buffered saline 
Res     =  Resveratrol 
RNA    =  Ribonucleic acid 
rpm     =  Revolutions per minute 
ss      =  Single-stranded 
T47D    =  Female ductal carcinoma cell line, differentiated epithelial  
        substrain 
T47D.Luc  =  Cell line T47D, stably transfected with an estrogen-    
        responsive luciferase reporter gene 
Tet     =  Tetracycline 
Tris-EDTA  =  Tris-ethylenediamine tetraacetic acid solution 
tRNA    =  total RNA, also: transfer RNA 
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